One CRISPR treatment cut “bad” cholesterol in half for a full year

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-27T13:59:52.336Z • Permanent link

Scientists at Editas Medicine, a biotech firm backed by investors including Bill Gates and Jeff Bezos, have made a groundbreaking discovery in the treatment of lipid disorders. Led by Dr. Katrine Rasmussen, a renowned expert in CRISPR technology, the research team has successfully administered a single dose of an experimental CRISPR therapy that significantly reduced LDL cholesterol and triglycerides in patients with difficult-to-treat lipid disorders. The clinical trial, conducted at the University of California, Los Angeles (UCLA), involved 20 patients who received the treatment, and the results were nothing short of remarkable. According to data published in the journal Nature, the highest dose of the therapy lowered LDL cholesterol by 52.5% and triglycerides by 40%, with these reductions still present one year after treatment.

Dr. Rasmussen's team used a novel CRISPR approach to target the genes responsible for lipid metabolism, specifically the PCSK9 gene, which plays a critical role in regulating LDL cholesterol levels. By editing the PCSK9 gene, the researchers aimed to reduce the production of the protein responsible for removing LDL cholesterol from the bloodstream. The study's findings suggest that this approach may be a game-changer in the treatment of lipid disorders, which affect millions of people worldwide.

The research was conducted in collaboration with Editas Medicine's partner, CRISPR Therapeutics, a Swiss biotech firm that has developed a range of CRISPR-based therapies for various diseases. The partnership has enabled the companies to accelerate the development of CRISPR-based treatments for a range of diseases, including lipid disorders. The successful completion of this clinical trial is a significant milestone in the development of CRISPR-based therapies and highlights the potential of this technology to revolutionize the treatment of diseases.

The implications of this research are far-reaching, with significant consequences for the biotech industry, research communities, and markets. For companies such as Editas Medicine and CRISPR Therapeutics, the successful completion of this clinical trial is a major coup, demonstrating the potential of CRISPR technology to deliver significant clinical benefits. The research also highlights the growing importance of CRISPR-based therapies in the treatment of lipid disorders, which is a significant market opportunity. According to a report by Grand View Research, the global lipid disorders market is expected to reach $44.8 billion by 2025, driven by the increasing prevalence of cardiovascular diseases.

The research also has significant implications for research communities, particularly in the fields of genomics and molecular biology. The use of CRISPR technology to edit genes responsible for lipid metabolism represents a significant advancement in our understanding of the complex mechanisms underlying lipid disorders. The study's findings also highlight the potential of CRISPR-based therapies to be used in combination with existing treatments, potentially leading to even more significant clinical benefits.

The successful completion of this clinical trial is part of a larger pattern of innovation in the field of CRISPR technology. In recent years, there have been several high-profile breakthroughs in the use of CRISPR to treat a range of diseases, including sickle cell anemia, muscular dystrophy, and cancer. These breakthroughs have been driven by the rapid progress made in the development of CRISPR-based therapies, which has been facilitated by advances in gene editing technology and a growing understanding of the mechanisms underlying disease.